{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:26:29Z","timestamp":1792736789991,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.coviro.2013.03.001","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T12:47:55Z","timestamp":1365079675000},"page":"217-224","source":"Crossref","is-referenced-by-count":40,"title":["Intervention strategies for emerging viruses: use of antivirals"],"prefix":"10.1016","volume":"3","author":[{"given":"Yannick","family":"Debing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Jochmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2013.03.001_sbref0005","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2013.03.001_bib0010","series-title":"Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control\u2014New Edition","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.coviro.2013.03.001_sbref0015","doi-asserted-by":"crossref","first-page":"e1752","DOI":"10.1371\/journal.pntd.0001752","article-title":"Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials","volume":"6","author":"Simmons","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2013.03.001_bib0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.antiviral.2012.12.002","article-title":"Experimental therapies for yellow fever","volume":"97","author":"Julander","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/v2040826","article-title":"Antiviral therapy for hepatitis C virus: beyond the standard of care","volume":"2","author":"Delang","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2013.03.001_bib0030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/JVI.06225-11","article-title":"Ligand-bound structures of the dengue virus protease reveal the active conformation","volume":"86","author":"Noble","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2012.09.007","article-title":"Structural biology of dengue virus enzymes: towards rational design of therapeutics","volume":"96","author":"Noble","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-3-642-27340-7_12","article-title":"HCV-specific directly acting antiviral drugs","volume":"369","author":"Delang","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0045","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Lin","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2013.03.001_bib0050","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1128\/AAC.00140-10","article-title":"Inhibition of dengue virus RNA synthesis by an adenosine nucleoside","volume":"54","author":"Chen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0470","doi-asserted-by":"crossref","unstructured":"Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh HL, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L et al.: A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2012, in press.","DOI":"10.1093\/infdis\/jis470"},{"key":"10.1016\/j.coviro.2013.03.001_bib0060","doi-asserted-by":"crossref","first-page":"14362","DOI":"10.1074\/jbc.M110.214189","article-title":"Functional analysis of two cavities in flavivirus NS5 polymerase","volume":"286","author":"Zou","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2013.03.001_bib0065","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1074\/jbc.M110.179184","article-title":"Small molecule inhibitors that selectively block dengue virus methyltransferase","volume":"286","author":"Lim","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2013.03.001_bib0070","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1128\/JVI.05468-11","article-title":"Inhibition of dengue virus by targeting viral NS4B protein","volume":"85","author":"Xie","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0075","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00074-09","article-title":"Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay","volume":"53","author":"Patkar","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0080","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1128\/JVI.02510-10","article-title":"Inhibition of dengue virus through suppression of host pyrimidine biosynthesis","volume":"85","author":"Wang","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2012.07.008","article-title":"Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial","volume":"96","author":"Watanabe","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.antiviral.2008.04.002","article-title":"A case for developing antiviral drugs against polio","volume":"79","author":"Collett","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.coviro.2012.02.009","article-title":"Recent advances in the molecular epidemiology and control of human enterovirus 71 infection","volume":"2","author":"McMinn","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcp.2011.08.016","article-title":"Combating enterovirus replication: state-of-the-art on antiviral research","volume":"83","author":"Thibaut","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1473-3099(02)00277-3","article-title":"FDA panel rejects common cold treatment","volume":"2","author":"Senior","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2013.03.001_bib0110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3851\/IMP1838","article-title":"Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073","volume":"16","author":"Kouiavskaia","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2013.03.001_bib0115","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0120","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2006.03.011","article-title":"Rhinovirus chemotherapy","volume":"71","author":"Patick","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0475","doi-asserted-by":"crossref","unstructured":"Tan J, George S, Kusov Y, Perbandt M, Anem\u00fcller S, Mesters JR, Norder H, Coutard B, Lacroix C, Leyssen P et al.: 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol 2013, in press.","DOI":"10.1128\/JVI.01123-12"},{"key":"10.1016\/j.coviro.2013.03.001_bib0130","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1128\/JVI.74.9.4146-4154.2000","article-title":"Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives","volume":"74","author":"Shimizu","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3201\/eid1404.070439","article-title":"Potential use of antiviral agents in polio eradication","volume":"14","author":"De Palma","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2013.03.001_sbref0140","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/cr.2012.129","article-title":"Coxsackievirus mutants that can bypass host factor PI4KIII\u03b2 and the need for high levels of PI4P lipids for replication","volume":"22","author":"van der Schaar","year":"2012","journal-title":"Cell Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0145","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1128\/AAC.00934-08","article-title":"Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307","volume":"53","author":"De Palma","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0150","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/JVI.02249-10","article-title":"Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity","volume":"85","author":"Arita","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.27.1.102","article-title":"Controlled trial of enviroxime against natural rhinovirus infections in a community","volume":"27","author":"Miller","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0160","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2009.07.024","article-title":"Replication cycle of chikungunya: a re-emerging arbovirus","volume":"393","author":"Solignat","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2013.03.001_bib0165","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/jmv.22019","article-title":"Chikungunya disease and chloroquine treatment","volume":"83","author":"Delogu","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0170","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.fitote.2012.05.004","article-title":"Chemical constituents of Anacolosa pervilleana and their antiviral activities","volume":"83","author":"Bourjot","year":"2012","journal-title":"Fitoterapia"},{"key":"10.1016\/j.coviro.2013.03.001_bib0175","doi-asserted-by":"crossref","first-page":"e28923","DOI":"10.1371\/journal.pone.0028923","article-title":"Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays","volume":"6","author":"Pohjala","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2013.03.001_bib0180","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1021\/np300637t","article-title":"Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of Chikungunya virus replication","volume":"75","author":"Bourjot","year":"2012","journal-title":"J Nat Prod"},{"key":"10.1016\/j.coviro.2013.03.001_bib0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.antiviral.2011.03.182","article-title":"In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant","volume":"90","author":"Delogu","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0480","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.01.002","article-title":"Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus","volume":"98","author":"Bassetto","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0195","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2013.03.001_bib0200","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2013.03.001_bib0205","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein\u2013ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2013.03.001_bib0210","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2013.03.001_bib0215","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0220","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","article-title":"The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus","volume":"12","author":"Tanner","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0230","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1002\/anie.200701021","article-title":"Bismuth complexes inhibit the SARS coronavirus","volume":"46","author":"Yang","year":"2007","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.coviro.2013.03.001_bib0235","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00957-12","article-title":"Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase","volume":"56","author":"Adedeji","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virusres.2011.03.017","article-title":"Clinical presentation of hepatitis E","volume":"161","author":"Aggarwal","year":"2011","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0245","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2011.01.016","article-title":"From barnyard to food table: the omnipresence of hepatitis E virus and risk for zoonotic infection and food safety","volume":"161","author":"Meng","year":"2011","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0250","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2013.03.001_bib0255","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/hep.25505","article-title":"The global burden of hepatitis E virus","volume":"55","author":"Rein","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2013.03.001_bib0260","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2013.03.001_sbref0265","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-153-2-201007200-00257","article-title":"Brief communication: case reports of ribavirin treatment for chronic hepatitis E","volume":"153","author":"Mallet","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2013.03.001_bib0270","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2010.08.002","article-title":"Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection","volume":"139","author":"Kamar","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2013.03.001_bib0275","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.healun.2011.03.013","article-title":"Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation","volume":"30","author":"Chaillon","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.coviro.2013.03.001_bib0280","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/j.1600-6143.2012.04200.x","article-title":"Chronic hepatitis E in heart transplant recipients","volume":"12","author":"Pischke","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2013.03.001_bib0285","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1086\/650488","article-title":"Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation","volume":"50","author":"Kamar","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2013.03.001_bib0290","doi-asserted-by":"crossref","first-page":"479","DOI":"10.7326\/0003-4819-155-7-201110040-00017","article-title":"Treatment of chronic hepatitis E in a patient with HIV infection","volume":"155","author":"Dalton","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coviro.2013.03.001_bib0295","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jcv.2011.06.004","article-title":"Treatment of severe hepatitis E by ribavirin","volume":"52","author":"Gerolami","year":"2011","journal-title":"J Clin Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.virusres.2011.01.015","article-title":"Hepatitis E virus cell culture models","volume":"161","author":"Okamoto","year":"2011","journal-title":"Virus Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0305","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1128\/JVI.00146-12","article-title":"Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depended on an inserted human gene segment acquired by recombination","volume":"86","author":"Shukla","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0310","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.0910108106","article-title":"Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein","volume":"107","author":"Roymans","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2013.03.001_bib0315","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1183\/09031936.00005610","article-title":"Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model","volume":"38","author":"Olszewska","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coviro.2013.03.001_bib0320","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.79.20.13105-13115.2005","article-title":"Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase","volume":"79","author":"Liuzzi","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0325","series-title":"WHO Expert Consultation on Rabies\u2014First Report","author":"World Health Organization","year":"2005"},{"key":"10.1016\/j.coviro.2013.03.001_bib0330","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1128\/AAC.36.8.1750","article-title":"Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine","volume":"36","author":"Lockhart","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0335","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2013.03.001_bib0340","first-page":"69","article-title":"Effect of amantadine on rhabdovirus infection","volume":"11","author":"Superti","year":"1985","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0345","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/bmj.299.6703.830","article-title":"Failure of interferon alfa and ribavirin in rabies encephalitis","volume":"299","author":"Warrell","year":"1989","journal-title":"Br Med J"},{"key":"10.1016\/j.coviro.2013.03.001_bib0350","first-page":"443","article-title":"Rabies in China: recommendations for control","volume":"70","author":"Kureishi","year":"1992","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coviro.2013.03.001_bib0355","first-page":"33","article-title":"Treatment of rabies in mice and foxes with antiviral compounds","volume":"32","author":"Bussereau","year":"1988","journal-title":"Acta Virol"},{"key":"10.1016\/j.coviro.2013.03.001_oref0360","doi-asserted-by":"crossref","unstructured":"Jackson AC: Current and future approaches to the therapy of human rabies. Antiviral Res; 2013, in press.","DOI":"10.1016\/j.antiviral.2013.01.003"},{"key":"10.1016\/j.coviro.2013.03.001_bib0365","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever","volume":"5","author":"Mendenhall","year":"2011","journal-title":"PLos Negl Trop Dis"},{"key":"10.1016\/j.coviro.2013.03.001_bib0370","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1016\/j.bmcl.2012.05.035","article-title":"SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity","volume":"22","author":"Burgeson","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2013.03.001_bib0375","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bmcl.2012.11.093","article-title":"Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles","volume":"23","author":"Burgeson","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2013.03.001_bib0380","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bmcl.2012.11.095","article-title":"Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole","volume":"23","author":"Dai","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coviro.2013.03.001_bib0385","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2217\/fmb.11.132","article-title":"Progress in the experimental therapy of severe arenaviral infections","volume":"6","author":"Gowen","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0390","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: medical and public health management","volume":"287","author":"Boro","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2013.03.001_bib0395","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2009.10.015","article-title":"Efficacy of favipiravir (T-705) and T-1106 purazine derivatives in phlebovirus disease models","volume":"86","author":"Gowen","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0405","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10096-009-0728-2","article-title":"The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising","volume":"28","author":"Tasdelen Fisgin","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.coviro.2013.03.001_bib0410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2007.11.002","article-title":"Treatment of Crimean-Congo hemorrhagic fever","volume":"78","author":"Ergonul","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_sbref0415","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coviro.2012.03.001","article-title":"Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries","volume":"2","author":"Ergonul","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0420","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/srep00811","article-title":"Transmission of Ebola virus from pigs to non-human primates","volume":"2","author":"Weingartl","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2013.03.001_bib0425","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/095632020101200406","article-title":"Intracellular phosphorylation of carbocyclic 3-deazaadenosine, an anti-Ebola virus agent","volume":"12","author":"Smee","year":"2011","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0430","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-3542(00)00066-8","article-title":"Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-l-homocysteine hydrolase inhibitor","volume":"45","author":"Bray","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_sbref0435","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann\u2013Pick C1 is essential for Ebola virus infection","volume":"477","author":"C\u00f4t\u00e9","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2013.03.001_bib0440","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/JVI.01456-10","article-title":"Identification of a small-molecule entry inhibitor for filoviruses","volume":"85","author":"Basu","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2013.03.001_bib0445","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/jm1008715","article-title":"Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry","volume":"54","author":"Yermolina","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.coviro.2013.03.001_bib0450","first-page":"87","article-title":"FGI-104: a broad-spectrum small molecule inhibitor of viral infection","volume":"1","author":"Kinch","year":"2009","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0455","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.06.001","article-title":"Development of a broad-spectrum antiviral with activity against Ebola virus","volume":"83","author":"Aman","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2013.03.001_bib0460","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1128\/AAC.01315-09","article-title":"Antiviral activity of a small-molecule inhibitor of filovirus infection","volume":"54","author":"Warren","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2013.03.001_bib0465","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2011.10.011","article-title":"Identification of an antioxidant small-molecule with broad-spectrum antiviral activity","volume":"93","author":"Panchal","year":"2012","journal-title":"Antiviral Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625713000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625713000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T20:40:00Z","timestamp":1562877600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625713000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1879625713000254"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2013.03.001","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}